204 related articles for article (PubMed ID: 9060524)
1. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.
Masters GA; Hoffman PC; Hsieh A; Drinkard LC; Mick R; Samuels BL; Guaspari A; Golomb HM; Vokes EE
J Clin Oncol; 1997 Mar; 15(3):884-92. PubMed ID: 9060524
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
[TBL] [Abstract][Full Text] [Related]
5. Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer.
Drinkard LC; Hoffman PC; Samuels BL; Watson S; Bitran JD; Golomb HM; Vokes EE
Semin Oncol; 1995 Apr; 22(2 Suppl 5):30-7; discussion 41-4. PubMed ID: 7537911
[TBL] [Abstract][Full Text] [Related]
6. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung.
Masters GA; Hoffman PC; Drinkard LC; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1998 Feb; 25(1 Suppl 2):8-14. PubMed ID: 9535205
[TBL] [Abstract][Full Text] [Related]
7. A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.
Tibaldi C; Baldini E; Ricci S; Conte PF
Anticancer Res; 1996; 16(5B):3213-5. PubMed ID: 8920792
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
Crawford J; O'Rourke MA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
[TBL] [Abstract][Full Text] [Related]
9. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
10. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.
Hejna M; Kornek GV; Raderer M; Marosi L; Schneeweiss B; Greul R; Weinländer G; Valencak J; Huber H; Scheithauer W
Oncology; 1998; 55(6):538-42. PubMed ID: 9778620
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Vallejo C; Romero A; Perez J; Cuevas M; Lacava J; Sabatini C; Dominguez M; Rodriguez R; Barbieri M; Romero Acuña L; Romero Acuña J; Langhi M; Amato S; Salvadori M; Ortiz E; Machiavelli M; Leone B
Am J Clin Oncol; 1996 Dec; 19(6):584-8. PubMed ID: 8931677
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.
Baldini E; Tibaldi C; Chella A; Angeletti CA; Romanini A; Andrei A; Algeri R; Silvano G; Conte PF
Semin Oncol; 1994 Jun; 21(3 Suppl 4):12-5. PubMed ID: 8209271
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study.
Rey F; Astoul P; Marqueste L; Petite JM; Boutin C; Viallat JR
Am J Clin Oncol; 1998 Oct; 21(5):518-22. PubMed ID: 9781613
[TBL] [Abstract][Full Text] [Related]
16. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
Ahn JB; Ko WK; Lee JG; Shim KY; Jeung HC; Park JO; Yoo NC; Kim BS; Kim SK; Kim SK; Kim JH
Am J Clin Oncol; 2000 Dec; 23(6):622-8. PubMed ID: 11202811
[TBL] [Abstract][Full Text] [Related]
17. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 1999; 56(4):301-7. PubMed ID: 10343194
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
[TBL] [Abstract][Full Text] [Related]
20. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
